USA: ER Editor: We’re running a report by American physician Dr. Meryl Nass and France’s France Soir site. We also recommend this report by Megan Redshaw for Children’s Health Defense, titled Pfizer Pushes for 4th Shot, Says 3 Doses ‘Not That Good’ Against Infections. A couple of noteworthy things (and we remind readers that Pfizer CEO Bourla’s medical claim to fame is as a VET):
“Every year, you need to go to get your flu vaccine,” Bourla said during an interview with NBC News. “It’s going to be the same with COVID. In a year, you will have to go and get your annual shot for COVID to be protected.”
That will mean even more sales — and more profits — from the vaccine, reported WRCBtv, a CBS subsidiary.
During a February 2021 earnings call, Bourla told analysts, big banks and investors the company could make significant profits by charging higher prices and implementing routine booster doses for new variants of the virus.
During the Barclays’ Global Health Conference in March 2021, CFO Frank D’Amelio said Pfizer didn’t see this as a one-time event, but “as something that’s going to continue for the foreseeable future.”
And:
New UK data suggest vaccines aren’t effective
According to data published on Substack by Alex Berenson, a former New York Times reporter, hospitalizations and deaths in the UK “remain stubbornly high and overwhelmingly occur in vaccinated people.”
Last month, 90% of the 1,000 Britons who died each week of COVID were vaccinated. During the four weeks ending Feb. 27, 397 unvaccinated people in Britain died of COVID compared to 3,512 who were vaccinated.
We recommend reading the rest of this CHD report.
********
Pfizer CEO says 4th shot needed, while Europe’s FDA says doing so risks “overloading the immune system” and might damage your immunity. Who would you trust?
Pfizer’s Bourla says we need a 4th shot. Pfizer sold $36.8 billion dollars’ worth of COVID vaccines in 2021, making its vaccine the top-selling pharmaceutical product in history. Pfizer has estimated its COVID vaccine sales for 2022 at $32 billion.
Albert Bourla says we need a 4th dose of his magic money-making elixir, but his company is also working on a universal coronavirus vaccine (a 2nd magic elixir), which we will only need once a year.
Albert Bourla, PhD, CEO of Pfizer, said a second booster shot of the COVID-19 vaccine is necessary for protection against infection, according to a March 13 interview with CBS News.
Dr. Bourla said the third dose of the COVID-19 vaccine provides protection from hospitalization and death, but “it’s not that good against infections” and the protection is relatively short-lived. Pfizer is preparing data for the FDA about the need for a fourth dose.
“Many variants are coming,” Dr. Bourla told CBS. “And omicron was the first one that was able to evade in a skillful way the immune protection that we were giving. But also, in all that the duration of the protection, it doesn’t last very long.”
…In February, the CDC published a study showing the efficacy of booster shots of Pfizer-BioNTech and Moderna vaccines waned after about four months, but still provided significant protection from hospitalizations during the omicron surge.
Dr. Bourla also told CNBC that Pfizer is developing a vaccine that will protect against all COVID-19 variants, including omicron, for at least a year. He expects to review data from trials on the long-term vaccine by the end of the month.
But Dr. Marco Cavaleri, a top regulator at Europe’s FDA, called the European Medicines’ Agency (EMA), says this may weaken the immune response.
According to Reuters:
The European Union’s drug regulator on Tuesday expressed doubts about the need for a fourth booster dose of COVID-19 vaccine and said there is currently no data to support this approach as it seeks more data on the fast-spreading Omicron variant.
“While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy,” the European Medicines Agency’s Head of Vaccines Strategy, Marco Cavaleri, told a media briefing.
The EMA official raised concerns that a strategy of giving boosters every four months hypothetically poses the risk of overloading people’s immune systems and leading to fatigue in the population.
Cavaleri also said more data on the impact of the new variant on vaccines and a better understanding of the evolution of the current wave were needed to decide whether an Omicron-specific vaccine was needed.
“It is important that there is a good discussion around the choice of the composition of the vaccine to make sure that we have a strategy that is not just reactive … and try to come up with an approach that will be suitable in order to prevent a future variant,” he said.
The EMA said it was currently in conversation with vaccine developers in case there is a need for an updated vaccine but added that any such change would need to be coordinated globally.
Source
********
A fourth dose of vaccine announced without any studies completed
FRANCE SOIR
“Pfizer will soon submit data on a fourth dose of its Covid-19 vaccine to US regulators” Albert Bourla, CEO of Pfizer.
A less dangerous sub-variant of Omicron
The Prime Minister and the Minister of Health have announced the possibility of a rebound in the epidemic in France. Unsurprisingly, the lifting of the vaccination pass on March 14 does not prevent the government from continuing the vaccination campaign.
In an exclusive interview with Le Parisien, Jean Castex announced the opening of the fourth dose for people aged 80 and over as well as for immunocompromised people from Monday March 14. This second booster is intended for people “who have received their booster dose for at least three months.” The announced objective: to better protect the most fragile people ” faced with a gradual loss of their immunity,” according to the Prime Minister.
The absence of a clinical study on the fourth dose
” I don’t really understand, France is going to start administering a 4th dose of vaccine to people over 80 years old while, I quote, the studies on the 4th booster dose and on the specific injection with omicron are still in progress, ”asks Christine Cotton, biostatistician and author of a methodological expert report in which she denounced the many biases and the information still missing.
He explained that he had reviewed the new data from the various studies on his Covid vaccine. A study on the fourth dose of the vaccine currently available and a study on a new vaccine that is supposed to protect against several variants of coronavirus.
“The results look encouraging ,” Bourla said in an interview with Bloomberg Television’s “Balance of Power With David Westin,” noting that Pfizer still needs to gather more information.
Bourla expects Pfizer to present to the U.S. Food and Drug Administration, either this month or early April, data on a fourth dose that may help restore immunity, along with results from a study looking at a version that specifically targets the Omicron variant. The injections were developed in collaboration with BioNTech SE, based in Germany.
A fourth dose with contested success tested in several countries
Faced with the progression of the Omicron variant, some countries have chosen to respond very quickly by deciding to administer a fourth dose. This was the case of Israel (ER: whose Jewish residents, not Palestinian ones, have been used royally by Pfizer), which decided on December 21 on a fourth dose for the over 60s, for people with comorbidities and for caregivers.
A few days after the start of this campaign and while a study suggested disappointing efficacy against the new variant, the highest scientific authorities in the country, including Professor Cyrille Cohen, recognized that the vaccine worked very poorly on the Omicron variant. In a vitriolic letter, Professor Ehud Qimron did not hesitate to speak of the failure of this vaccination policy.
See also: It’s time to admit your failure”: Professor Ehud Qimron charges the Israeli authorities
Source
Join: 👉 https://t.me/acnewspatriots
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of AC.NEWS
Disclaimer: This article may contain statements that reflect the opinion of the author. The contents of this article are of sole responsibility of the author(s). AC.News will not be responsible for any inaccurate or incorrect statement in this article www.ac.news websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner. Reprinting this article: Non-commercial use OK. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Discussion about this post